Log In
Print
BCIQ
Print
Print this Print this
 

Rilutek, riluzole

  Manage Alerts
Collapse Summary General Information
Company Sanofi
DescriptionGlutamate antagonist
Molecular Target Metabotropic glutamate receptor subtype 5 (mGluR5) (GRM5)
Mechanism of ActionMetabotropic glutamate receptor subtype 5 (mGluR5) modulator
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationAmyotrophic lateral sclerosis (ALS)
Indication DetailsTreat amyotrophic lateral sclerosis (ALS); Treat amyotrophic lateral sclerosis (ALS) of both bulbar and limb onset
Regulatory Designation

Partner

Covis Pharma S.a.r.l.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today